Nanotechnology-Based Drug Delivery Systems for Treatment of Tuberculosis-A Review

Autor(es)

da Silva, Patricia Bento ^[1] ; de Freitas, Eduardo Sinesio ^[2] ; Bernegossi, Jessica ^[1] ; Goncalez, Maira Lima ^[1] ; Sato, Mariana Rillo ^[1] ; Fujimura Leite, Clarice Queico ^[2] ; Pavan, Fernando Rogerio ^[2] ; Chorilli, Marius ^[1]

Afiliação do(s) autor(es)

^[1] Sao Paulo State Univ, Sch Pharmaceut Sci, Dept Drugs & Med, BR-14801902 Araraquara, SP - Brazil

^[2] Sao Paulo State Univ, Sch Pharmaceut Sci, Dept Biol Sci, BR-14801902 Araraquara, SP - Brazil

• Tipo de documento: Artigo de Revisão
• Fonte: JOURNAL OF BIOMEDICAL NANOTECHNOLOGY; v. 12, n. 2, p. 241-260, FEB 2016.
• Citações Web of Science: 20

Resumo

Tuberculosis (TB) is an infectious and transmissible disease that is caused by Mycobacterium tuberculosis and primarily affects the lungs, although it can affect other organs and systems. The pulmonary presentation of TB, in addition to being more frequent, is also the most relevant to public health because it is primarily responsible for the transmission of the disease. The to their low World Health Organization (WHO) recommends a combined therapeutic regimen of several drugs, such as rifampicin (RIF), isoniazid (INH), pyrazinamide (PZA) and ethambutol (ETB). These drugs have low plasma levels after oral administration, due to their low water solubility, poor permeability and ability to be rapidly metabolized by the liver and at high concentrations. Furthermore, they have short t(1/2) (only 1-4 hours) indicating a short residence in the plasma and the need for multiple high doses, which can result in neurotoxicity and hepatotoxicity. Nanotechnology drug delivery systems have considerable potential for the treatment of TB. The systems can also be designed to allow for the sustained release of drugs from the matrix and drug delivery to a specific target. These properties of the systems enable the improvement of the bioavailability of drugs, can reduce the dosage and frequency of administration, and may solve the problem of non-adherence to prescribed therapy, which is a major obstacle to the control of TB. The purpose of this study was to systematically review nanotechnology-based drug delivery systems for the treatment of TB. (AU)

• Processo FAPESP: 13/14957-5 - Investigação do potencial contra tuberculose de uma nova classe de compostos furoxânicos e compostos nanoestruturados de rutênio(II) e cobre(II)
• Beneficiário: Fernando Rogério Pavan
• Linha de fomento: Auxílio à Pesquisa - Apoio a Jovens Pesquisadores
• Processo FAPESP: 12/19568-4 - Avaliação do potencial de sistemas lipídicos nanoestruturados para administração cutânea de trans-resveratrol
• Beneficiário: Marlus Chorilli
• Linha de fomento: Auxílio à Pesquisa - Regular
• Processo FAPESP: 13/09265-7 - Avaliação do potencial de sistemas lipídicos nanoestruturados para administração de compostos de Cu(II) aplicáveis na otimização da terapia da tuberculose
• Beneficiário: Patrícia Bento da Silva
• Linha de fomento: Bolsas no Brasil - Pós-Doutorado